Premium
Successful treatment of diabetic gangrene with topical application of a mixture of peripheral blood mononuclear cells and basic fibroblast growth factor
Author(s) -
ASAI Jun,
TAKENAKA Hideya,
ICHIHASHI Kaori,
UEDA Eiichiro,
KATOH Norito,
KISHIMOTO Saburo
Publication year - 2006
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2006.00081.x
Subject(s) - gangrene , medicine , basic fibroblast growth factor , peripheral blood mononuclear cell , diabetes mellitus , surgery , growth factor , peripheral blood , peripheral , diabetic foot , immunology , endocrinology , biology , in vitro , biochemistry , receptor
Diabetic gangrene is a non‐healing skin ulcer that is often resistant to most common treatments. It is caused by microvascular disorders and an immunocompromised state which are induced by diabetes mellitus. We report a 65‐year‐old man with an aggressive, refractory diabetic gangrene on his left foot. Treatment of his diabetic gangrene with topical application of a mixture of peripheral blood mononuclear cells (PBMC) and basic fibroblast growth factor (bFGF) resulted in a dramatic improvement in a short time. The ulcer was completely closed and, in the past 6 months, no new ulceration has been observed. The patient is able to stand and walk by himself. Topical application of a mixture of PBMC and bFGF appears to be a useful, non‐invasive and convenient method for the treatment of diabetic gangrene.